GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ME Therapeutics Holding Inc (XCNQ:METX) » Definitions » Land And Improvements

ME Therapeutics Holding (XCNQ:METX) Land And Improvements : C$0.00 Mil (As of Feb. 2024)


View and export this data going back to 2023. Start your Free Trial

What is ME Therapeutics Holding Land And Improvements?

ME Therapeutics Holding's land and improvements for the quarter that ended in Feb. 2024 was C$0.00 Mil.


ME Therapeutics Holding Land And Improvements Historical Data

The historical data trend for ME Therapeutics Holding's Land And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ME Therapeutics Holding Land And Improvements Chart

ME Therapeutics Holding Annual Data
Trend Aug22 Aug23
Land And Improvements
- -

ME Therapeutics Holding Quarterly Data
Aug22 Dec22 May23 Aug23 Nov23 Feb24
Land And Improvements Get a 7-Day Free Trial - - - - -

ME Therapeutics Holding Land And Improvements Calculation

Land is the surface or crust of the earth, which can be used to support structures, and may be used to grow crops, grass, shrubs, and trees. Land is characterized as having an unlimited life (indefinite). Land improvement is a long-term asset which indicates the cost of the constructed improvements to land, such as driveways, walkways, lighting, and parking lots.


ME Therapeutics Holding (XCNQ:METX) Business Description

Comparable Companies
Traded in Other Exchanges
Address
177 Robson Street, Vancouver, BC, CAN, V6B 0N3
ME Therapeutics Holding Inc operates its business through ME Therapeutics. It is a preclinical-stage biotechnology company working on novel cancer-fighting drugs in the field of Immuno-Oncology (IO). It is developing preclinical data for its myeloid-targeted candidate assets using validated cancer models.

ME Therapeutics Holding (XCNQ:METX) Headlines

No Headlines